In This Section

Home / Learn / Cancer Types / Hematologic Malignancies / Reframing the Conversation: Effective Practices for Diffuse Large B-cell Lymphoma

Reframing the Conversation: Effective Practices for Diffuse Large B-cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL), is an aggressive disease affecting B-lymphocytes. Despite being aggressive, DLBCL is considered curable. There are many novel therapies and combination regimens currently being studied in clinical trials for the treatment of both newly diagnosed and relapsed/refractory DLBCL. Recently approved treatments, as well as those on the horizon, provide new hope for patients as therapeutic options become more targeted to and personalized for their disease.

With these recent advancements, community cancer programs need to be educated on the role these therapies will play in the community setting and how best to integrate these new treatments into practice. In response, ACCC has developed an educational initiative called Reframing the Conversation: Effective Practices for Diffuse Large B-cell Lymphoma. The aim of this project is to reframe the conversation between patients and providers to incorporate new therapy advancements, set expectations with patients about their treatment journey, and give them more confidence that there is new hope.

This will be accomplished by:

  • Conducting a landscape analysis (literature review) to curate existing literature and resources
  • Completing 2 focus groups with multidisciplinary cancer care team members, patients, and caregivers with the goals of identifying areas of need within this patient population
  • Creating and deploying an infographic depicting a “Communication Process Roadmap” highlighting effective practices to support patients with DLBCL applied along the care continuum.
  • Highlighting 3 ACCC member programs with experience managing patients with DLBCL
  • Producing podcasts and vodcasts that will highlight the learnings from the practice profile focus groups
  • Producing publications summarizing the findings of this project

For more information on this project, please contact the ACCC Provider Education department.

Our Supporters

This project is made possible by support from AbbVie, Genmab, & Genentech.